Welcome to the UK and Éire Glaucoma Society website.
UK and Éire Glaucoma Society (UKEGS) is a non-profit national scientific society, and part of Glaucoma UK, which aims to:
Our next UKEGS Conference will be a face to face meeting on 21 and 22 April 2022, hosted by UKEGS President Prof Pete Shah at the IET Austin Court in central Birmingham.
We’re delighted to share some details of our upcoming conference programme. A complete programme will be released in the New Year alongside booking details.
Here’s a sample of the exciting presentation sessions at our upcoming conference.
Diagnostics, Big Data and AI – glaucoma recovery
Chaired by Professor David Garway-Heath & Ms Nishani Amersinghe
Surgical videos of tips and tricks
Chaired by Professor Gus Gazzard & Mr Jim Kirwan
Managing surgical complications
Chaired by Mr Imran Masood & Mr Gok Ratnarajan
Helping patients live with glaucoma
Chaired by Professor David Crabb & Mr Jim Kirwan
The global perspective and advanced disease
Chaired by Professor Rupert Bourne, Professor Anthony King & Ms Rashmi Mathew
We are now accepting abstracts for poster and oral presentations at the meeting.
We are also accepting applications for the £50,000 UKEGS research award. This ophthalmology-focused open call grant is open to all UKEGS members. The closing date for applications is 28 February 2022.
Our venue for UKEGS Conference 2022 is located near the centre of Birmingham, in the heart of the UK. Only a few minutes walk from Birmingham New Street Station
IET Birmingham: Austin Court
80 Cambridge Street
To give you a flavour of UKEGS annual meetings, here are some photos from past events.
UKEGS proudest achievement is its annual conference aimed mainly at the ophthalmology community, but increasingly of interest to optometrists and others. The conference is usually held over two days towards the end of each year and is hosted in the hometown of the current President.
The RCOphth and UKEGS have collaboratively developed a clinical tool for classification of patients with glaucoma into strata of risk for significant future sight loss and an estimate of resource requirement for managing the patient. The tool acknowledges diagnosis, stage of disease, complexity of disease, rate of disease progression, life expectancy, ocular and systemic comorbidities, dependency and socio-economic deprivation. The eye-level classification should be used to stratify patients according to the worse eye which has remaining useful vision, for which the patient is willing to undergo treatment to retain sight.
This guidance provides pragmatic advice on recommencing care for glaucoma patients based on clinical expertise from a variety of clinical settings around the UK. The scope of this document is to provide advice for the ‘recovery phase’ rather than the acute lockdown phase. We anticipate this phase will cover perhaps the next six months or so. Some of the points will be germane to longer term ‘post COVID-19’ services.
Glaucoma UK and UKEGS co-fund a glaucoma research award of £50,000 – £70,000 for high quality research that enhances the detection and treatment of glaucoma and improves patients’ quality of life.